An observational study in Cardiotoxicity, Lung Cancer Stage III and Lung Cancer Stage II, sponsored by Abramson Cancer Center at Penn Medicine. Active, not recruiting at 8 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.
Sponsored by Abramson Cancer Center at Penn Medicine · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Cardiotoxicity by Abramson Cancer Center at Penn Medicine — 1 open to participants now, 5 under way, none of them phase 3. Cardiotoxicity · Abramson Cancer Center at Penn Medicine.
Among the 10 studies in Cardiotoxicity by Abramson Cancer Center at Penn Medicine, this one is one of 2 that started in 2020, is one of 8 observational ones, and was the 4th registered.
263 studies on the registry are indexed under Cardiotoxicity; 76 are open to participants now.
Browse Cardiotoxicity studies →1 of the 10 studies in Cardiotoxicity by Abramson Cancer Center at Penn Medicine is open now, in 1 country. Recruiting first, the newest first:
Abramson Cancer Center at Penn Medicine · Sites in United States
Ages 22+
By country, each count listing its studies:
Of the 51 Cardiotoxicity studies recruiting now, 38 (75%) set no upper age limit and 8 (16%) stop at 75 or younger; 7 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 1
First in 2018; this study’s year is marked. 2 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 221 is above the median of 111 across 125 observational studies indexed under Cardiotoxicity.
Median enrollment 88 across the 2 interventional studies, 128 across the 8 observational. Of the 5 that completed or were terminated, 2 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
Abramson Cancer Center at Penn Medicine is the lead sponsor of 462 studies on the registry; 88 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 14 (42%) have results posted.
3 of the studies in Cardiotoxicity by Abramson Cancer Center at Penn Medicine that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06332131Abramson Cancer Center at Penn MedicineEffects of Immune Checkpoint Inhibitors on Coronary Microvasculature | 2026-11 |
| NCT04305613Abramson Cancer Center at Penn MedicineCardiotoxicity in Locally Advanced Lung Cancer Patients Treated With Chemoradiation Therapy | 2026-12 |
| NCT06211413Abramson Cancer Center at Penn MedicineHypertension and Arrhythmias in CLL Patients Treated With BTK Inhibitors | 2027-06 |
Add all 3 to your calendar (.ics) → With an account.
Among the 10 studies in Cardiotoxicity by Abramson Cancer Center at Penn Medicine, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This observational cohort will evaluate the cardiovascular effects of chemoradiation used to treat locally advanced, non-small cell lung cancer. Patients will be enrolled prior to the start of therapy and followed during and for at least 2 years after therapy with echocardiograms, nuclear stress tests, blood sampling, and quality of life surveys.
Lung cancer is both the most common malignancy worldwide and the leading cause of cancer death in the US. While radiation therapy is highly effective for many solid tumors, thoracic radiation therapy carries a risk of cardiovascular morbidity and mortality that limits critical gains in cancer control and survival. The investigators will perform detailed cardiovascular phenotyping using biologic and imaging markers to define functional and physiologic perturbations that occur with radiation therapy. The study will provide insights into how cardiovascular risk factors and disease impact these biologic and functional changes. The investigators will also determine which radiotherapy dose-volume metrics are indicative of subclinical cardiotoxicity.
Patients with lung cancer will be enrolled from the radiation oncology clinics at participating sites.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with locally advanced non-small cell lung cancer
Other: Chemoradiation
Patients will be treated with definitive concurrent chemoradiation with curative intent as determined by their medical and radiation oncologists. We will consider timing of initiation and discontinuation, type, and cumulative dose of platinum based chemotherapy. We will also consider dose, duration, and type of immunotherapy. Radiation therapy will be delivered via proton or proton therapy. Our primary radiation therapy dose-volume exposures are whole heart volumetric dose. As secondary exposures, we will comprehensively define radiation therapy dose parameters to the right ventricle, entire left ventricle, left ventricle segments, coronary arteries, and mean heart dose.
High Sensitivity C-Reactive Protein
Change in hsCRP from baseline
Time frame: up to 12 months
Growth Differentiation Factor 15
Change in GDF-15 from baseline
Time frame: up to 12 months
Placental Growth Factor
Change in PIGF from baseline
Time frame: up to 12 months
Left Ventricular Strain
Change in echo-derived measures of LV peak systolic strain (longitudinal) from baseline
Time frame: up to 12 months
Ventricular Arterial Coupling
Change in echo-derived measures of ventricular-arterial coupling (Ea/Ees) from baseline
Time frame: up to 12 months
Coronary Flow Reserve (CFR_
Change in PET/CT derived CFR from baseline
Time frame: 6 months
Overall Survival (2 Year)
All-cause mortality assessed by electronic medical record (EMR) review
Time frame: 24 months
Cardiovascular Specific Mortality (2 Year)
Cardiovascular specific mortality assessed by EMR review
Time frame: 24 Months
Major Cardiovascular Events (2 Year)
Incidence of MCE assessed by EMR review and patient interview
Time frame: up to 24 months
High-Sensitivity Troponin T
Change in hsTnT from baseline
Time frame: up to 12 months
N-type pro Brain Natriuretic Peptide
Change in NTproBNP from baseline
Time frame: up to 12 months
Left Ventricular Ejection Fraction (2D)
Change in echo-derived LVEF from baseline
Time frame: up to 12 months
Right Ventricular Fractional Area Change (RAC)
Change in echo-derived RAC from baseline
Time frame: up to 12 months
Right Ventricular Longitudinal Strain
Change in echo-derived RV longitudinal strain from baseline
Time frame: up to 12 months
Circumferential Strain
Change in echo-derived circumferential strain from baseline
Time frame: up to 12 months
Diastolic Function
Change in echo-derived measures of diastolic function from baseline
Time frame: up to 12 months
Valvular Disease
Change in echo-derived measures of valvular disease (degree of regurgitation or stenosis) from baseline
Time frame: up to 12 months
Left Ventricular Ejection Fraction (3D)
Change in 3D echocardiography derived LVEF from baseline
Time frame: up to 12 months
Left Ventricular systolic strain (3D)
Change in 3D echocardiography derived measures of LV systolic strain from baseline
Time frame: up to 12 months
Left Ventricular Twist and Torsion
Change in 3D echocardiography derived measures of LV twist and torsion from baseline
Time frame: up to 12 months
Global and Regional Myocardial Blood Flow at Rest
Change in PET/CT derived measures of global and regional myocardial blood flow at rest from baseline
Time frame: up to 6 months
Global and Regional Myocardial Blood Flow at Stress
Change in PET/CT derived measures of global and regional myocardial blood flow at stress from baseline
Time frame: up to 6 months
FACIT Fatigue Score
Change in FACIT Fatigue score from baseline. Score ranges from 0-52. Higher scores indicated less fatigue.
Time frame: up to 5 years
FACIT Dyspnea Score
Change in FACIT Dyspnea score from baseline. Score ranges from 0-30. Higher scores indicate more dyspnea.
Time frame: up to 5 years
Godin Leisure Time Exercise Score
Change in Godin Leisure Time Exercise Score from baseline. Higher scores indicate higher levels of physical activity.
Time frame: up to 5 years
Overall Survival (5 Year)
All Cause Mortality assessed by National Death Index Search performed 5 years after the last patient is enrolled.
Time frame: 5-8 years
Cardiovascular Specific Mortality (5 Year)
Cardiovascular Specific Mortality by National Death Index Search performed approximately 5 years after the final patient is enrolled.
Time frame: 5-8 Years
Major Cardiovascular Events (5 Year)
Incidence of 5-Year MCE by EMR review and patient interview
Time frame: 5 years
NCI Patient Reported Outcomes Common Terms and Criteria for Adverse Events (PRO-CTCAE)
Incidence of symptomatic adverse events as assessed by NCI's PRO-CTCAE
Time frame: 5 Years
Plan to share: Undecided — Participants may opt in to allowing data and/or banked samples to be used for future research and shared with other researchers. A detailed plan for sharing IPD will be finalized at a later date, and may depend in part on how many participants elect this option. Additional supporting information may be shared, including the study protocol and informed consent form.
No publications or documents are linked to this record.
Started Sep 2020 (actual). Primary completion is estimated for Dec 2026, 75 months after the start.
Of 69 non-industry observational studies under Cardiotoxicity, half reached primary completion within 69 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 122. This study's planned 75 months is close to that.
Counting every sponsor, half of 71 studies reached it within 69 months; a quarter within 33 and three quarters within 122.
Primary completion moved once since we started tracking on Sep 25, 2026: Sep 2026 → Dec 2026, on Oct 5, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Abramson Cancer Center at Penn Medicine →